Journal of Diabetes Research, published by HINDAWI LTD, is a leading open-access journal dedicated to advancing the understanding and management of diabetes. Established in 2013, the journal has swiftly gained recognition, achieving a commendable Q2 ranking in both the categories of Endocrinology and Diabetes and Metabolism, as well as in Biochemistry, Genetics and Molecular Biology. With an impressive Scopus ranking of #42 out of 244 in its field, the journal provides a platform for cutting-edge research that addresses the multifaceted challenges posed by diabetes. Offering unrestricted access to its articles since its inception, the journal aims to foster collaboration and exchange of innovative ideas among researchers, clinicians, and students worldwide. It is particularly vital for those engaged in diabetes research, as it publishes influential studies that impact clinical practices and enhance patient outcomes. For academics and professionals seeking to contribute to the growing body of knowledge in diabetes, the Journal of Diabetes Research serves as a valuable resource.

HORMONE AND METABOLIC RESEARCH, published by GEORG THIEME VERLAG KG, stands as a reputable platform in the fields of biochemistry, endocrinology, and metabolism since its establishment in 1969. This peer-reviewed journal provides critical insights and advancements in the intricate relationships between hormones and metabolic processes, catering to researchers, healthcare professionals, and students alike. With an impressive convergence of knowledge spanning over five decades, it maintains a commendable Q3 ranking in multiple categories, including Biochemistry, Clinical Biochemistry, and Endocrinology, highlighting its contribution to cutting-edge scientific discourse. Although not an open-access journal, it offers a plethora of access options for readers and institutions, ensuring that vital research reaches those who need it most. Located in Stuttgart, Germany, the journal is positioned at the forefront of influential research in hormone and metabolic studies, emphasizing its importance for ongoing investigations into health and disease.

Diabetology & Metabolic Syndrome is a premier open-access journal published by BMC, dedicated to advancing the field of endocrinology, diabetes, and metabolic syndrome. Since its inception in 2009, the journal has established itself as a leading platform for original research, reviews, and clinical studies, offering comprehensive insights into the complexities of metabolic diseases. With an impressive ranking in the 2023 category quartiles as Q1 in both Endocrinology, Diabetes and Metabolism, and Internal Medicine, it stands among the top-tier journals in its field. Researchers will appreciate its strong emphasis on disseminating critical findings that influence clinical practices and public health policies. Accessible to a global audience, Diabetology & Metabolic Syndrome's commitment to open access enables the distribution of high-quality research without barriers, fostering an inclusive environment for knowledge sharing. With a strategic focus on the intersection of diabetes management and metabolic disorders, this journal is essential for professionals seeking to stay abreast of the latest developments and contribute to a vital area of healthcare.

DIABETES CARE, published by the American Diabetes Association, is a premier journal dedicated to advancing the understanding and management of diabetes and related metabolic disorders. Since its inception in 1978, this journal has maintained a commitment to disseminating high-quality research, evidenced by its prestigious ranking in the Q1 category across multiple fields including Advanced and Specialized Nursing, Endocrinology, Diabetes and Metabolism, and Internal Medicine. With an impressive impact factor and distinguished Scopus rankings, DIABETES CARE serves as an essential resource for researchers, clinicians, and students alike, facilitating the exchange of knowledge and fostering innovation in diabetes care. Although not an open-access publication, the journal offers various ways to access groundbreaking studies and advancements in the field. This commitment to excellence reflects the journal's vital role in shaping diabetes research and clinical practices globally.

Diabetes Therapy is a prominent open access journal published by SPRINGER HEIDELBERG, dedicated to advancing our understanding of diabetes management and therapeutic strategies. Since its inception in 2010, the journal has provided a platform for high-quality research, showcasing innovative studies and clinical advances aimed at improving care for individuals with diabetes. With an established impact factor and categorized within the Q2 quartile in both Endocrinology, Diabetes and Metabolism and Internal Medicine in 2023, it ranks among the top journals in its field, reflecting its significant contribution to medical knowledge. Researchers, healthcare professionals, and students benefit from its comprehensive coverage of critical topics, ranging from pharmacological advancements to lifestyle interventions and cutting-edge technologies in diabetes management. With a Scopus rank placing it 35th in Internal Medicine, and 68th in Endocrinology, Diabetes, and Metabolism, Diabetes Therapy is recognized for its robust peer-reviewed content, making it an essential resource for anyone engaged in diabetes research and care.

Therapeutic Advances in Endocrinology and Metabolism is a premier open-access journal published by SAGE Publications Ltd that has established itself as a leading platform for research in the field of endocrinology, diabetes, and metabolism. With a commitment to disseminating high-quality research, the journal aims to advance our understanding of therapeutic interventions and innovations in the management of endocrine disorders. Since its inception in 2010, it has garnered a strong reputation, attaining a Q1 quartile ranking in 2023 in its category and boasting a respectable Scopus rank of #53 out of 244, positioning it within the 78th percentile. As an open-access journal since 2019, Therapeutic Advances in Endocrinology and Metabolism ensures that valuable research findings are accessible to a global audience, fostering collaboration and knowledge sharing among researchers, clinicians, and students alike. The journal's multifaceted objectives encompass the publication of original research, reviews, and clinical studies that contribute to the evolving dialogue surrounding endocrine health. By delivering timely and robust content, it serves as an indispensable resource for those striving to make significant contributions to this vital area of medical science.

DIABETES, published by the American Diabetes Association, is a premier journal in the field of endocrinology, diabetes, and metabolism, renowned for its rigorous peer-reviewed research since its inception in 1952. With an impressive impact factor and classified in the Q1 category for both Endocrinology, Diabetes and Metabolism and Internal Medicine as of 2023, it holds a prestigious position within the scholarly community, ranked 17th out of 244 in its specialization. The journal's objective is to disseminate cutting-edge research and advance scientific understanding to ultimately improve diabetes patient care and management. While it does not offer open access options, the journal remains a vital resource for researchers, professionals, and students involved in diabetes-related studies. The ongoing dedication to excellence by the authors, reviewers, and editors ensures that DIABETES continues to be a pivotal platform for innovation and knowledge in the fight against diabetes.

DIABETES-METABOLISM RESEARCH AND REVIEWS, published by WILEY, is an esteemed academic journal focusing on the forefront of research in the fields of endocrinology, diabetes, and metabolism. Since its inception in 1999, this journal has become a crucial resource for researchers, professionals, and students, boasting an impressive impact factor that reflects its high citation rates and contribution to the field. With a 2023 classification of Q1 in several categories including Endocrinology and Internal Medicine, it ranks among the top journals globally, demonstrating its significant influence and authority. The journal serves as a platform for the dissemination of innovative research, reviews, and methodologies that advance understanding and treatment of metabolic disorders. By offering valuable insights and fostering collaboration within the scientific community, DIABETES-METABOLISM RESEARCH AND REVIEWS is essential reading for anyone involved in diabetes research and clinical practice.

The Journal of Diabetes, published by WILEY, is a premier Open Access platform since 2022, dedicated to advancing knowledge in the fields of endocrinology, diabetes, and metabolism. With an ISSN of 1753-0393 and an E-ISSN of 1753-0407, this journal provides a vital resource for researchers and practitioners looking to keep up with the latest findings and trends in diabetes management and treatment. As of 2023, it holds a commendable Q2 rating in its category and ranks #78 out of 244 in the Scopus classification, placing it in the 68th percentile, thus affirming its significance in the academic community. Covering a timeline from 2009 to 2024, the journal invites submissions that contribute to the understanding of diabetes pathophysiology, innovative therapies, and clinical practices, making it an essential read for anyone dedicated to improving patient outcomes in diabetes care.

Metabolic Syndrome and Related Disorders is an esteemed journal published by MARY ANN LIEBERT, INC, focusing on the multifaceted aspects of metabolic syndrome, including its interaction with chronic diseases such as diabetes, cardiovascular conditions, and obesity. Since its inception in 2003, this journal has established itself as a vital resource for researchers, healthcare professionals, and students dedicated to advancing knowledge in the fields of endocrinology, internal medicine, and metabolic disorders. With an impact factor reflective of its academic significance, Metabolic Syndrome and Related Disorders is recognized within the Q2 and Q3 quartiles in its respective categories, solidifying its reputation among scientific and clinical communities. Although it does not currently offer open access options, the journal remains committed to disseminating high-quality research and reviews that foster innovative solutions and improve patient outcomes. The journal's gradual convergence towards 2024 presents an exciting opportunity for continued exploration and dialogue about metabolic-related health challenges.